MedTrace Logo

A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece

NCT04965870 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-03-07

No results posted yet for this study

Summary

Collection of real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population.

Conditions

Interventions

DRUG

Trifluridine/Tipiracil

Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.

Sponsors & Collaborators

  • Servier

    collaborator INDUSTRY

  • Hellenic Study Group of Psychoneuroimmunology in Cancer

    lead NETWORK

Principal Investigators

  • ANNA KOUMARIANOU, PhD · 4th Department of Internal Medicine, Attikon University Hospital

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2021-10-31
Completion
2021-12-20

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04965870 on ClinicalTrials.gov